RELX Deep Dive: RELX is Mis-Categorized in the AI Selloff
Thesis
Relx PLC ($RELX) ADRs is mispriced relative to intrinsic value due to broad AI-disruption fears, while FY2025 results confirm the company is an AI beneficiary with 7% organic growth and expanding product capabilities. The stock should re-rate toward $42–56 over the next 6–12 months as the market differentiates data-moat businesses from vulnerable content publishers.
The core asymmetry here is a category error by the market. RELX has sold off sharply from prior highs and, despite recovering from its 52-week low near $27.57, the ADR still trades around $35.68. A meaningful part of that weakness appears tied to investor fears that AI will disrupt publishing and information businesses. However, RELX’s business model is fundamentally different from a content publisher. It owns canonical, proprietary, continuously-updated datasets across legal (LexisNexis), scientific (Elsevier/Scopus), and risk analytics (RELX Risk Solutions) that cannot be replicated by generative AI models. These datasets are inputs to enterprise AI workflows, not outputs replaceable by them.
The FY2025 results, released February 12, 2026, provide critical confirmation, approximately 7% underlying revenue growth across all segments, with explicit management commentary on AI-enabled product launches and industry recognition. This directly contradicts the disruption narrative. The 34.8% adjusted operating margin and 15.4% ROIC reflect the pricing power of data assets with massive switching costs and embedded workflow value. RELX generated £3.735B of cash from operations, incurred £525M of capital expenditure, primarily capitalized development rather than physical capex, and produced £2.313B of free cash flow before dividends, underscoring the strength of the company’s cash-generation profile.
The announced £2.25B buyback program signals management confidence and provides mechanical EPS support. More importantly, the broader market’s misclassification creates a window where a wide-moat compounder with mid-teens ROIC trades at a meaningful discount to intrinsic value.
Updating fair value for confirmed 7% growth, assuming FY2025 FCF of ~$3.0B, FCF per ADR share of approximately $1.55–1.65, and applying a high-20s to low-30s FCF multiple, yields a fair value range of about $42–56. The midpoint of $49 represents ~37% upside from current levels.
Key risks include the possibility that the AI disruption narrative intensifies and sentiment-driven selling pushes the stock to new lows before re-rating, even if the fundamentals remain intact. Open-access mandates could erode Elsevier STM margins over time and pressure one of the company’s most profitable segments. A strong USD could create translation headwinds on GBP-denominated earnings and mechanically reduce ADR EPS. ADR liquidity constraints and thin U.S. options markets could also create execution slippage for investors using the ADR tactically.
Potential catalysts include market differentiation of data-moat businesses from content publishers as AI adoption matures, execution of the £2.25B share buyback program at current prices, and H1 2026 interim results demonstrating continued AI product revenue growth.
Bottom line, I think RELX looks like a high-quality, wide-moat compounder that the market is still misreading through an overly broad AI-disruption lens. I do not view it as a no-risk bargain, especially with open-access, currency, and sentiment overhangs still in play, but I think the current price understates the durability of its data assets, embedded workflows, and cash-generation profile. At these levels, my view is that RELX offers attractive upside for a patient investor, with the bullish case resting more on steady re-rating and durable execution than on any dramatic near-term catalyst.